Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 5.1%

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) rose 5.1% on Thursday . The company traded as high as $2.86 and last traded at $2.86. Approximately 47,066 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 2,712,542 shares. The stock had previously closed at $2.72.

Analysts Set New Price Targets

TSHA has been the subject of a number of research reports. Needham & Company LLC lifted their price objective on Taysha Gene Therapies from $5.00 to $7.00 and gave the company a "buy" rating in a research note on Wednesday, March 20th. Cantor Fitzgerald reissued an "overweight" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Canaccord Genuity Group reissued a "buy" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. Chardan Capital boosted their target price on Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a "buy" rating in a research note on Thursday, March 21st. Finally, JMP Securities reissued a "market outperform" rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $6.57.

Taysha Gene Therapies Trading Down 1.5 %

The company has a 50-day moving average price of $2.28 and a 200-day moving average price of $2.12. The firm has a market capitalization of $501.21 million, a price-to-earnings ratio of -4.06 and a beta of 0.29. The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.08 and a current ratio of 4.08.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC boosted its position in shares of Taysha Gene Therapies by 2,035.0% during the 3rd quarter. FMR LLC now owns 24,527,801 shares of the company's stock worth $77,508,000 after acquiring an additional 23,378,974 shares in the last quarter. RA Capital Management L.P. purchased a new stake in shares of Taysha Gene Therapies in the 3rd quarter valued at about $58,373,000. RTW Investments LP purchased a new stake in shares of Taysha Gene Therapies in the 3rd quarter valued at about $53,382,000. Vanguard Group Inc. lifted its holdings in shares of Taysha Gene Therapies by 16.3% in the 4th quarter. Vanguard Group Inc. now owns 6,195,567 shares of the company's stock valued at $10,966,000 after purchasing an additional 867,703 shares during the last quarter. Finally, Avoro Capital Advisors LLC lifted its holdings in shares of Taysha Gene Therapies by 11.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 4,355,555 shares of the company's stock valued at $7,709,000 after purchasing an additional 430,555 shares during the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.